Who are C4 Therapeutics, Inc.'s main suppliers?

C4 Therapeutics, Inc. (CCCC) key suppliers include: Pfizer Inc., Pfizer Inc., BETTA-PHARMA, BETTA-INVESTMENT-HONG-KONG-LIMITED, Compugen Ltd. and 2 more. View the full supplier network at chainsifter.com/chain/CCCC.

Who are C4 Therapeutics, Inc.'s major customers?

C4 Therapeutics, Inc. (CCCC) key customers include: BETTA-PHARMACEUTICALS, ROCHE, AstraZeneca PLC, AstraZeneca PLC, Monte Rosa Therapeutics, Inc. and 13 more. View the full customer network at chainsifter.com/chain/CCCC.

What sector is C4 Therapeutics, Inc. in?

C4 Therapeutics, Inc. (CCCC) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

C4 Therapeutics, Inc. Suppliers, Customers & Supply Chain (CCCC)

7Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

C4 Therapeutics, Inc. (CCCC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

29Total relationships

3Distinct source URLs

10High confidence

0.751Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

C4 Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
PFE	Pfizer Inc.	92%	Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Dexamethasone (dex)
PFE	Pfizer Inc.	92%	Reciprocal relationship from PFE graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from PFE graph: Reciprocal relationship from CCCC graph: Pfizer supplying elranatamab (ELREXFI…
BETTA-PHARMA	BETTA-PHARMA	90%	Betta Pharma is responsible for all development, regulatory approval, manufacturing and commercialization costs in Greater China
BETTA-INVESTMENT-HONG-KONG-LIMITED	BETTA-INVESTMENT-HONG-KONG-LIMITED	80%	Betta Investment agreed to purchase 5,567,928 shares of the Company's common stock
CGEN	Compugen Ltd.	72%	Reciprocal relationship from CGEN graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from CGEN g…
GLUE	Monte Rosa Therapeutics, Inc.	72%	Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
KYMR	Kymera Therapeutics, Inc.	72%	Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…

C4 Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BETTA-PHARMACEUTICALS	BETTA-PHARMACEUTICALS	90%	License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China
ROCHE	ROCHE	85%	the Company and Roche agreed to collaborate in the research, development, manufacture and commercialization of target-binding degrader medicines
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, …
AZN	AstraZeneca PLC	72%	ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti…
GLUE	Monte Rosa Therapeutics, Inc.	72%	ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti…
GLUE	Monte Rosa Therapeutics, Inc.	72%	Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
KYMR	Kymera Therapeutics, Inc.	72%	Reciprocal relationship from KYMR graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force,…
KYMR	Kymera Therapeutics, Inc.	72%	ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti…
NRIX	Nurix Therapeutics, Inc.	72%	ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources, and ti…
NRIX	Nurix Therapeutics, Inc.	72%	Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing …
BIIB	Biogen Inc.	62%	Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC graph: tion rights under certain circumsta…
BIOGEN-MA-INC	BIOGEN-MA-INC	62%	tion rights under certain circumstances, including but not limited to insolvency or a material breach by the other party, subject to certain conditions. Roche Agreement accounting At commencement, th…
C4T-SECURITIES-CORPORATION	C4T-SECURITIES-CORPORATION	62%	cialization, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, lack of marketing and sales history, product liability, prote…
DOHME-LLC	DOHME-LLC	62%	en fully allocated. Merck License and Collaboration Agreement On December 11, 2023, the Company and Merck Sharp & Dohme, LLC, or Merck, entered into an exclusive license and collaboration agreement, …
EVERCORE-GROUP	EVERCORE-GROUP	62%	latory review of our product candidates; • the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any …
EVR	Evercore Inc.	62%	Reciprocal relationship from EVR graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from EVR graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from EVR grap…
MRK	Merck & Co., Inc.	62%	Reciprocal relationship from MRK graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CCCC graph: en fully allocated. Merck License and…
USA-LLC	USA-LLC	62%	andards and requirements, and insider trading laws. We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, CMOs, and consultants may engage in…

C4 Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CCCC-DEBT-8516	Warrants outstanding: 8.86	90%	xbrl warrant detail from xbrl 2026-03-31.
CCCC-DEBT-8517	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
CCCC-DEBT	Debt stack $58.4M	90%	Market cache reports total debt of $58.4M.

C4 Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for C4 Therapeutics, Inc..

C4 Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CCCC-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 125 tracked holders.

C4 Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
EVR	Evercore Inc.	100.00	1	['customer']
OLMA	Olema Pharmaceuticals, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
IDYA	IDEAYA Biosciences, Inc.	100.00	2
NRIX	Nurix Therapeutics, Inc.	100.00	1	['customer']
ALLO	Allogene Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
CGEN	Compugen Ltd.	100.00	1	['supplier']
GILD	Gilead Sciences, Inc.	100.00	2
DRTS	Alpha Tau Medical Ltd.	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer']
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
DEO	Diageo plc	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BIIB	Biogen Inc.	100.00	1	['customer']
MGNX	MacroGenics, Inc.	100.00	2

C4 Therapeutics, Inc. Supply Chain